Metraipolis › archive › dc_6dc1f98bf9dd

Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or… — Europe PMC PMID:41264726

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41264726
DOI
10.1093/ecco-jcc/jjaf198
License (as archived)
solo-consultazione
Archived
2026-11-07T05:15:39.063Z
SHA-256 of the archived text
15f1e6fb0d74d6ac5e164a83ede315209aadfbc3ed24600090c78755369d5b49
Stable URL of this page
https://metraipolis.com/documento/dc_6dc1f98bf9dd

How to cite

Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or… — Europe PMC PMID:41264726 — Europe PMC (en), https://europepmc.org/article/MED/41264726 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6dc1f98bf9dd (Metraipolis archive dc_6dc1f98bf9dd, sha256 15f1e6fb0d74d6ac5e164a83ede315209aadfbc3ed24600090c78755369d5b49)
BibTeX
@misc{dc6dc1f98bf9dd,
  title = {Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or… — Europe PMC PMID:41264726},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41264726},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6dc1f98bf9dd; sha256 15f1e6fb0d74d6ac5e164a83ede315209aadfbc3ed24600090c78755369d5b49},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41264726. Agents can read the archived copy with the MCP tool read_document.